IDEXX Laboratories (NASDAQ:IDXX) presented a mixed financial picture in the recently announced
Q3 2024 results. Despite surpassing earnings per share (EPS) estimates, the company suffered a stock price fall due to
missed revenue expectations and lowered guidance, sparking
Hedgeye to add IDEXX to its short idea list. However, the organization's respective Q3 income and EPS show robust growth, while intrinsic value calculations and FY 2024 earnings guidance display
strong financial outlook.
Third-quarter performance was firm, although lower than
Wall Street's forecasts. On the upside, AustralianSuper Pty Ltd lowered its stock holdings in the company, but Forsta AP Fonden increased theirs confirming investor confidence. While IDEXX's stock performance fluctuated, it overall outperformed competitors. A bull case theory for IDXX is also discernible among market players, attributed it to attractive financial prospects. However,
the Q3 report revealed a revenue miss, causing the stock to dip. The company's earnings are expected to grow constituted by its strong returns on capital but trailed the favorable shareholder returns over the past five years.
Idexx Laboratories IDXX News Analytics from Sat, 27 Apr 2024 07:00:00 GMT to Sat, 02 Nov 2024 22:25:00 GMT -
Rating 2
- Innovation 7
- Information 8
- Rumor -2
